Alpha Sense BI

MAY 28, 2024

The top three trending sectors—information technology, healthcare/biotech, and business and financial services— ushered in funding rounds over $100 million since the beginning of the year. Instead, experts agree that investors will likely turn to innovative start-up companies with promising growth plans and strong leadership teams.

Capital 69

Capital Startups Biotech Due Diligence 69

Alpha Sense BI

APRIL 29, 2024

Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

AUGUST 30, 2023

AI has become more prevalent in every part of asset management, from opportunity identification to due diligence to invest men t decision-making to perfor man ce analysis to ongoing portfolio management and more. As AI systems play a larger role in investment decisions, transparency and explainability become crucial.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. Inflationary pressures are forecasted to ease and new innovations are capturing the attention of consumers, investors, and executives across various industries.

Technology 69

Technology Technology Retail Biotech 69

Alpha Sense BI

MAY 5, 2023

M&A Trends by Industry Healthcare The COVID-19 pandemic ushered in a wave of unprecedented innovation, progress, and transformation to the healthcare industry in 2020. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines.

Biotech 97

Biotech Capital Banking Startups 97

Engage3

MAY 19, 2022

Ken served on the Board of Directors of Revionics between 2007-2011 and as Chief Scientist & VP of Innovations at SAP AG between 2006-2007. Tim Ouimet Founder & Board Observer Tim Ouimet is a Founder and Board Member at Engage3 and is a recognized industry innovator in retail pricing strategies.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

MARCH 13, 2024

According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs. In January, HATCo announced its intent to acquire Summa Health of Ohio , a non-profit healthcare system, with a focus to “put innovation in.”

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59